研究文章
特瑞普利单抗致ACTH缺乏型垂体炎合并进展性血细胞减少1例
摘要
关键词
参考
Postow MA,Sidlow R,Hellmann MD.Immune-Related Ad-verse Events Associated with Immune Checkpoint Blocka-de [J].N Engl J Med,2018,378(2):158-168.
Petrelli F, Ardito R, Borgonovo K, et al. Haematologicaltoxicities with immunotherapy in patients with cancer: asystematic review and meta analysis. Eur J Cancer, 2018,103: 7-16. doi: 10.1016/j.ejca.2018.07.129
中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤药物相关血小板减少诊疗专家共识(2023版)[J]. 中华医学杂志志,2023,103(33):2579-2590.
Khagi Y,Kurzrock R,Patel SP. Next generation predictive biomark ers for immune checkpoint inhibition[J]. Cancer Metastasis Rev,2017, 36(1):179-190.
FAJE A T, SULLIVAN R, LAWRENCE D, et al. Ipilimu-mab-induced hypophysitis:a detailed longitudinal analysisin a large cohort of patients with metastatic melanoma[J].J Clin Endocrinol Metab, 2014,99(11):4078-4085. DOI:1-0.1210/jc.2014-2306.
BAI XF, LIN XH, ZHENG KN, etal. Mapping endocrinetoxicity spectrum of immune checkpoint inhibitors:a disp-roportionality analysis using the WHO adverse drug react-ion database, VigiBase[J].Endocrine, 2020, 69(3):670-681.DOI:10.1007/s12020-020-02355-9.
CASTINETTI F, ALBAREL F, ARCHAMBEAUD F, etal.French Endocrine Society Guidance on endocrine side eff-ects of immunotherapy[J/OL]. Endocr Relat Cancer, 2019,26(2):G1-G18[2024-11-25]. https://pubmed.ncbi.nlm.nih.go-v/30400055/. DOI:10.1530/ERC-18-0320.
MAHZARI M, LIU D, ARNAOUT A, et al. Immune chec-kpoint inhibitor therapy associated hypophysitis[J]. ClinMed Insights Endocrinol Diabetes, 2015, 8:21-28. DOI:1-0.4137/CMED.S22469.
中华医学会内分泌分会免疫内分泌学组.免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识[J].中华内分泌代谢杂志,2020,37(1):1-16.17

